Professional Documents
Culture Documents
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin
molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often
do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn cut
off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful
attacks or "crises," damage to various organs and shortened life spans. People with SCD often suffer
unpredictable painful crises Nigerian several
http://www.nigeriaembassyusa.org/index.php?page=about-nigeria times a year lasting from a few
hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria,
that number is believed to be approximately 4 million, and worldwide at least 12 million individuals
are afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on anticancer,
antiviral (including AIDS), antifungal, antimalarial and antibacterial products from natural sources,
including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals
(natural herbal drugs) and other proprietary technologies, including those used in the treatment of
orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these
diseases. Its recent focus and resources have been directed primarily toward the development and
launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the
Nigerian regulatory approval now in hand, Xechem will now turn to the commercialization of the
drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to
NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has
licensed from Virginia Commonwealth University.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of
the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934,
as amended, which are intended to be covered by safe harbors created hereby. Such forward looking
statements involve known and unknown risks and uncertainties.
http://www.businesswire.com/news/home/20060711005212/en/Nigerian-President-Olusegun-Obasanj
o-Launches-Xechems-Sickle